From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Three life-science prizes were awarded for advances in gene therapies. Opthalmologists Jean Bennett and Albert Maguire, and ...

The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...

The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...

Investigating a common gene in three very different species—salamanders, mice and zebrafish—scientists have discovered the ...

Pfizer announced in February 2025 that it was taking Beqvez (fidanacogene elaparvovec), its gene therapy for hemophilia B, ...

The treatment for primary immunodeficient diseases is varied. As mentioned before, the most common type of primary immunodeficient disease are antibody deficiencies. Either patients don't make enough ...

Detroit patients getting HEMGENIX report life‑changing results; trial data show 94% off prophylaxis at five years.

After its bet on a rare eye disease gene therapy ended in a phase 3 fail last year, Johnson & Johnson is now returning the ...

Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...

Sarepta Therapeutics Inc.'s bid for the full Federal Circuit’s review of a revived gene-therapy patent dispute with RegenxBio ...

Andhra Pradesh Minister Nara Lokesh on Saturday oversaw the administration of a Rs 16-crore injection, Zolgensma, to a baby girl in Kurnool district, with part of the cost reportedly bridged through ...